TP53 and acute myeloid leukemia: Interestingly, the initial, recently reported findings of the Beat AML programme found that TP53 and ASXL1 (one of the recurrent mutated chromatin genes) were associated with a general pattern of drug resistance in an ex vivo 122 small molecule inhibitor screen (21).